| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_25d4714039f3a908f101654b3e5757b3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-572
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-21 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-04 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-19 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 |
| filingDate |
2020-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6aa3d69d5ef2cb0dd86b0754718ec5e8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee6012fd2218cdb0fa45042ba35a3a5b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f84bf1255e3d4a01a509ddb54006ad0 |
| publicationDate |
2022-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-114222762-A |
| titleOfInvention |
Fusion protein for tuberculosis vaccine |
| abstract |
The present invention relates to fusion proteins based on mycobacterium tuberculosis antigen polypeptides for use in the prevention, inhibition or treatment of infection and/or disease caused by a tuberculosis complex species. In particular, the invention relates to fusion proteins comprising antigens and/or ESAT-6 repeats that do not elicit an immune response against BCG. The fusion protein may comprise a combination of early and late antigens. Furthermore, the invention relates to vaccines, immunogenic compositions and pharmaceutical compositions comprising the fusion protein. |
| priorityDate |
2019-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |